Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 88 points (-0.5%) at 17,785 as of Tuesday, May 31, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,627 issues advancing vs. 1,333 declining with 171 unchanged.

The Drugs industry currently sits up 2.0% versus the S&P 500, which is down 0.2%. Top gainers within the industry include

Celator Pharmaceuticals

(

CPXX

), up 70.9%,

Neurocrine Biosciences

(

NBIX

), up 8.1%,

Alnylam Pharmaceuticals

(

ALNY

), up 7.2%,

Grifols

(

GRFS

), up 2.8% and

Novo Nordisk A/S

(

NVO

), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Merck

(

MRK

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Merck is down $0.29 (-0.5%) to $56.19 on light volume. Thus far, 2.8 million shares of Merck exchanged hands as compared to its average daily volume of 8.8 million shares. The stock has ranged in price between $56.16-$56.72 after having opened the day at $56.49 as compared to the previous trading day's close of $56.48.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $156.3 billion and is part of the health care sector. Shares are up 6.9% year-to-date as of the close of trading on Friday. Currently there are 5 analysts that rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Merck

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Merck Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Shire

(

SHPG

) is down $1.69 (-0.9%) to $185.27 on heavy volume. Thus far, 3.4 million shares of Shire exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $185.01-$189.24 after having opened the day at $187.83 as compared to the previous trading day's close of $186.96.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Shire plc, a biotech company, together with its subsidiaries, engages in the research, development, licensing, manufacture, marketing, distribution, and sale of medicines for patients with rare diseases and other select conditions. Shire has a market cap of $36.9 billion and is part of the health care sector. Shares are down 8.8% year-to-date as of the close of trading on Friday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Shire

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Shire Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Johnson & Johnson

(

JNJ

) is down $0.64 (-0.6%) to $112.42 on light volume. Thus far, 2.8 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.4 million shares. The stock has ranged in price between $112.32-$113.63 after having opened the day at $113.27 as compared to the previous trading day's close of $113.06.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. Johnson & Johnson has a market cap of $311.0 billion and is part of the health care sector. Shares are up 10.1% year-to-date as of the close of trading on Friday. Currently there are 9 analysts that rate Johnson & Johnson a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Johnson & Johnson Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).